TY  - GEN
AU  - Laniece Delaunay, Charlotte
AU  - Melo, Aryse
AU  - Maurel, Marine
AU  - Mazagatos, Clara
AU  - Goerlitz, Luise
AU  - O'Donnell, Joan
AU  - Oroszi, Beatrix
AU  - Sève, Noémie
AU  - Rodrigues, Ana Paula
AU  - Martínez-Baz, Iván
AU  - Meijer, Adam
AU  - Mlinarić, Ivan
AU  - Latorre-Margalef, Neus
AU  - Lazar, Mihaela
AU  - Pérez-Gimeno, Gloria
AU  - Dürrwald, Ralf
AU  - Bennett, Charlene
AU  - Túri, Gergő
AU  - Rameix-Welti, Marie-Anne
AU  - Guiomar, Raquel
AU  - Castilla, Jesús
AU  - Hooiveld, Mariëtte
AU  - Kurečić Filipović, Sanja
AU  - Samuelsson Hagey, Tove
AU  - Dijkstra, Frederika
AU  - Borges, Vítor
AU  - Ramos Marín, Violeta
AU  - Bacci, Sabrina
AU  - Kaczmarek, Marlena
AU  - Kissling, Esther
AU  - European Primary Care Vaccine Effectiveness Group
PY  - 2024
DO  - 10.1016/j.vaccine.2024.05.067
SN  - 0264-410X
UR  - https://hdl.handle.net/20.500.12105/25486
AB  - In autumn 2023, European vaccination campaigns predominantly administered XBB.1.5 vaccine. In a European multicentre study, we estimated 2023 COVID-19 vaccine effectiveness (VE) against laboratory-confirmed symptomatic infection at primary care level...
LA  - eng
PB  - Elsevier
KW  - COVID-19
KW  - Europe
KW  - Multicentre study
KW  - SARS-CoV-2
KW  - Test-negative design
KW  - Vaccine effectiveness
KW  - Adolescent
KW  - Adult
KW  - Aged
KW  - COVID-19 Vaccines
KW  - COVID-19
KW  - Case-Control Studies
KW  - Europe
KW  - Female
KW  - Humans
KW  - Immunization Programs
KW  - Male
KW  - Middle Aged
KW  - Primary Health Care
KW  - SARS-CoV-2
KW  - Vaccination
KW  - Vaccine Efficacy
KW  - Young Adult
TI  - Effectiveness of COVID-19 vaccines administered in the 2023 autumnal campaigns in Europe: Results from the VEBIS primary care test-negative design study, September 2023-January 2024
TY  - research article
ER  -